Itβs hard not to get addicted to this.
From side conversations with @MEBirnbaum to an incredible result for patients. So proud of the Kelonia team for all the hard work it took to make this real.
Check out @Steph_Gaglione's amazing preprint introducing a highly scalable (and inexpensive) approach to TCR synthesis that enables library-on-library screening of TCRs + antigens π!
Thrilled to share our preprint! We introduce TCRAFT, a method to assemble tens of thousands of TCRs at <$1 each, unlocking high-throughput functional TCR screening from single-cell data.
π§΅@kochinstitute@MEBirnbaum@MITChemE@MIT
https://t.co/zifGBP4p7k
here's a peek of Dr. Perez showing this work - how diverse CAR libraries (inputs) can be leveraged to generate useful datasets that describe differential CAR phenotypes (outputs) at his thesis defense yesterday π
super lucky to be your lab mate & play a small part in this work!
An incredibly impressive body of work from the newly-minted PhD @calebrperez comparing clinical candidate CAR-T architectures head-to-head at single cell resolution, shedding light on mechanisms of differential CAR-T efficacy in vivo with insights into better construct design π
Excited to share some of my PhD work was pre-printed! Using single-cell sequencing, we took a deep look at a library of CAR signaling architectures to try to identify signal-intrinsic drivers of CAR-T functionπ§΅π @MEBirnbaum@kochinstitute@MITdeptofBE
https://t.co/DHbwlFQlnB
The authors then applied their TScan-II methodology to uncover antigens in cancer, autoimmunity, & infectious disease across many different MHC class II alleles & TCRs
Their screens uncovered antigens recognized by clonally-expanded CD4+ T cells from SjΓΆgren's syndrome patients
For their last trickπͺ, the authors introduced the candidate human TCR antigen-binding variable region atop a murine TCR constant region resulting in a human-mouse hybrid TCR that reduces cross-reactivity with the endogenous TCR
They termed these chimeras "centaur T cells"ππ
For the T cell side of the equation, they made use of the granule-releasing properties of primary CD8+ T cells, but introduced a CD4 co-receptor alongside a candidate T cell receptor (TCR) of interest
But what if the introduced TCR mispairs with the endogenous CD8+ T cell's TCR?
Wrote a Spotlight piece together w/ lab mate @amandaochan & @MEBirnbaum covering an impressive new methodology from @elledge_stephen's group that enables MHC class II antigen discovery for CD4+ T cells called TScan-II
https://t.co/v5CTgyZqMh
They also needed to introduce a reporter of T cell antigen recognition
The reporter is an infrared fluorescent protein (IFP) that only becomes fluorescent upon exposure to cytotoxic granzyme B (GzB), representing a functional & sortable readout of cognate CD4+ T cell recognition
But to do so, the authors needed to engineer both the antigen presenting cells (APCs), alongside the primary T cells used
For the APCs, they modified HEK-293 cells (eHEK-293-II) to lack MHC class I, but present MHC class II allele(s) of interest alongside appropriate machinery
TScan-II allows for genome-scale interrogation of MHC class II antigens using endogenous processing & presentation machinery of antigen libraries, alongside physiological T cell activation & degranulation (GzB) π
https://t.co/nVCO97nd9L
new @runthelistpod episode is now out hosted on @MHMedical's AccessMedicine webpage!
best part about it?
you can search for key words & phrases to more easily listen to high-yield content π€―
https://t.co/gk4dowcBPG
We're back with another podποΈ!
Ep 97: Approach to Dysphagia
https://t.co/i96iBINONn
Host @NavinKumarMD discusses dysphagia workup w/ RTL's own @WalkerReddMD
1. ENTER #mRNAvaccines for #pancreaticcancer! Long-term #PDAC survivor story PART3.
"Do #PDACs REALLY have vaccine neoantigens (NAs)"? (arenβt they lowly mutated?)
If each patient = own NAs, how do you vaccinate?
Maybe mRNA? But how?
@Nature https://t.co/d1SgGgdVHq
ππ½ [1/32]
@ESmithMDPhD@DanaFarber this is so incredibly exciting, congrats to you @ESmithMDPhD & your team! such an amazing turnaround from the 2019 publication to now π